Product Overview
Bay 60-7550 is a potent and selective inhibitor of 3',5'-cyclic nucleotide phosphodiesterase type 2 (PDE2) with IC50 value of 4.7 nM for human recombinant PDE2.In the signal transduction process, the redundant second messenger cGMP is degraded by the cyclic nucleotide phosphodiesterases. Among the 11 families of PDEs, PDE2 can hydrolyse both cAMP and cGMP and control the levels of both them in the areas which are important for memory formation and storage. Therefore, the inhibition of PDE2 activity is thought to be good to improve memory functions via enhancing neuronal plasticity. Bay 60-7550 is a highly potent and selective inhibitor of PDE2. It increased the levels of cGMP in both hippocampal slices and cultured neurons. In animal models, Bay 60-7550 was found to have positive effects on there cognition performance. As a potent PDE2 inhibitor, Bay 60-7550 suppressed activity of the purified enzyme obtained from bovine heart with an IC50 value of 2 nM. It showed no significant effects on other PDEs including PDE1, 3B, 4B, 5, 7B, 8A, 9A, 10A and 11A. For other similar receptors or enzymes, the IC50 values of Bay 60-7550were all more than 10 μM. Besides that, Bay 60-7550 had no effects on adenosine deaminase even though the concentration was up to 10 μM. In cultured rat cortical neurons and hippocampal neurons, the combination therapy of Bay 60-7550 and Bay 41-8543 resulted in notably increase of cGMP levels. In rat hippocampal slices, treatment of Bay 60-7550 caused a significant higher potentiation of the field excitatory postsynaptic potential slope. In rodent models, oral administration of Bay 60-7550 at doses of 1 and 3 mg/kg resulted in improvement of memory performance. In addition, Bay 60-7550 was found to mediate decrease of oxidative stress in mice models. It significantly reversed the decrease of both percentage of open arm entries and percentage of open arm time induced by oxidative stress at dose of 3 mg/kg in the elevated plus-maze test.
Chemical Name
2-[(3,4-dimethoxyphenyl)methyl]-7-[(2R,3R)-2-hydroxy-6-phenylhexan-3-yl]-5-methyl-1H-imidazo[5,1-f][1,2,4]triazin-4-one